{"id":58794,"date":"2024-01-29T19:02:36","date_gmt":"2024-01-29T18:02:36","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/"},"modified":"2024-01-29T19:02:36","modified_gmt":"2024-01-29T18:02:36","slug":"anganys-first-clinical-trial-concludes-on-time-and-with-positive-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/","title":{"rendered":"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results"},"content":{"rendered":"
\n

QUEBEC CITY–(BUSINESS WIRE)–ANGANY inc. announces the completion on schedule of its first clinical trial, assessing the safety and allergenicity of its therapeutic candidate against human allergy to cats. The study results were consistent throughout the 20 human adult cat allergic participants. The final results and conclusions of this clinical trial will be submitted to a major scientific journal.<\/p>\n

<\/a>
<\/a><\/p>\n

\nSkillfully conducted and on-time<\/b><\/p>\n

\nANGANY\u2019s First-in-Human study of its novel biologic ANG-101 candidate vaccine against cat allergy concluded in December 2023, ahead of schedule. The enthusiasm for a novel solution for cat allergy facilitated enrollment. The skills and professional expertise of Dr. Guy Scadding and Pr. Stephen Durham, the study investigators, were central in conducting this open-label clinical study safely and swiftly. ANGANY is now able to move further ahead with the preparation of its next phase study of the same asset.<\/p>\n

\nFavorable results<\/b><\/p>\n

\nPreliminary accounts showed consistency in the results and an excellent safety profile. ANG-101 was associated with significant hypoallergenicity, a marker of safety and long sought-after feature in allergy therapeutics, when compared to a commercial cat dander extract.<\/p>\n

\nImportant publication<\/b><\/p>\n

\nDetailed results and conclusions of the study will be submitted to a top-tier scientific journal for publication. The results should also be presented at the EAACI\u2019s Annual Meeting to be held in Valencia in May 2024.<\/p>\n

\nQuotes<\/b><\/p>\n

\n\u201cWe are very pleased with the rapid completion and results of this First-in-Human study. The demonstrated safety and hypoallergenicity of ANG-101 represent the cornerstone of the further clinical development of this breakthrough technology<\/i>,\u201d stated Patrick Colin, BPharm, PhD, ANGANY\u2019s vice-president of clinical development.<\/p>\n

\nWe are delighted to report on a significant step forward in the company\u2019s development. This milestone couldn\u2019t have been reached without the expertise of our investigators, the participants\u2019 commitment, and the dedication of our team. I would like to extend my warm thanks to all,\u201d <\/i>stated Christine Guillen, CEO of ANGANY.<\/p>\n

\nAbout ANGANY<\/b><\/p>\n

\nANGANY is a Franco-Canadian private clinical-stage biotech company pioneering a new immunotherapy approach to overcome the challenge of allergy. ANGANY\u2019s eBioparticle\u2122 technology makes for biologics of a new generation to be administered as vaccines. ANGANY’s eBioparticle-Potentiated Immunotherapy\u2122 also opens-up new prospects in fields of application beyond allergy in human and animal health, notably in cancer immunotherapy.<\/p>\n

\nRead the full press release:
\n
https:\/\/angany.com\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors Relations:<\/b>
Guy Tropper MD
\n
Executive Vice-President
\n
guy.tropper@angany.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

QUEBEC CITY–(BUSINESS WIRE)–ANGANY inc. announces the completion on schedule of its first clinical trial, assessing the safety and allergenicity of its therapeutic candidate against human allergy to cats. The study results were consistent throughout the 20 human adult cat allergic participants. The final results and conclusions of this clinical trial will be submitted to a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58794","6":"format-standard","7":"category-industry"},"yoast_head":"\nANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"QUEBEC CITY–(BUSINESS WIRE)–ANGANY inc. announces the completion on schedule of its first clinical trial, assessing the safety and allergenicity of its therapeutic candidate against human allergy to cats. The study results were consistent throughout the 20 human adult cat allergic participants. The final results and conclusions of this clinical trial will be submitted to a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-29T18:02:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240129566000\/en\/1981393\/21\/Angany_logo_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results\",\"datePublished\":\"2024-01-29T18:02:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/\"},\"wordCount\":409,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240129566000\\\/en\\\/1981393\\\/21\\\/Angany_logo_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/\",\"name\":\"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240129566000\\\/en\\\/1981393\\\/21\\\/Angany_logo_%282%29.jpg\",\"datePublished\":\"2024-01-29T18:02:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240129566000\\\/en\\\/1981393\\\/21\\\/Angany_logo_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240129566000\\\/en\\\/1981393\\\/21\\\/Angany_logo_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/","og_locale":"en_US","og_type":"article","og_title":"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results - Pharma Trend","og_description":"QUEBEC CITY–(BUSINESS WIRE)–ANGANY inc. announces the completion on schedule of its first clinical trial, assessing the safety and allergenicity of its therapeutic candidate against human allergy to cats. The study results were consistent throughout the 20 human adult cat allergic participants. The final results and conclusions of this clinical trial will be submitted to a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/","og_site_name":"Pharma Trend","article_published_time":"2024-01-29T18:02:36+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240129566000\/en\/1981393\/21\/Angany_logo_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results","datePublished":"2024-01-29T18:02:36+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/"},"wordCount":409,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240129566000\/en\/1981393\/21\/Angany_logo_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/","url":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/","name":"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240129566000\/en\/1981393\/21\/Angany_logo_%282%29.jpg","datePublished":"2024-01-29T18:02:36+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240129566000\/en\/1981393\/21\/Angany_logo_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240129566000\/en\/1981393\/21\/Angany_logo_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/anganys-first-clinical-trial-concludes-on-time-and-with-positive-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ANGANY\u2019s First Clinical Trial Concludes on Time and with Positive Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58794"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58794\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}